Transient interactions govern the interplay of biomolecules in virtually all processes of life. The analysis of molecular interactions is key for the discovery of new drugs and binding parameters such as affinity, avidity, and kinetic rates are helpful to select the most promising candidates during drug development.
I will describe our attempts to develop new methods and devices to measure biomolecular binding with surface biosensors, single-cell biosensors, and nanopores for affinity-selective single molecule detection. I will highlight applications concerning new drug modalities involving multi-specific small molecules and antibodies, and real-time binding measurements on living cancer cells.
Uli was trained in physics at TU Graz and completed his PhD scl in biophysics with Prof. Gerhard Abstreiter at TU Munich in 2005. He led a nanotechnology research group at the Walter Schottky Institute of TU Munich and was a junior fellow of the Institute of Advanced Study before founding Dynamic Biosensors GmbH in 2013, a company for research instruments, which enable the analysis of molecular interactions in drug discovery. Uli headed Dynamic Biosensors until it was acquired by Bruker in 2024.
Since 2024, he has been the director of the Kurt Schwabe Institute for Sensor Technologies, professor for Physical Chemistry at TU Dresden, and Chief Scientific Officer of Bruker Biosensors.
Uli’s research revolves around the analysis of molecular interactions, including methods to probe single cells and single molecules.
Transient interactions govern the interplay of biomolecules in virtually all processes of life. The analysis of molecular interactions is key for the discovery of new drugs and binding parameters such as affinity, avidity, and kinetic rates are helpful to select the most promising candidates during drug development.
I will describe our attempts to develop new methods and devices to measure biomolecular binding with surface biosensors, single-cell biosensors, and nanopores for affinity-selective single molecule detection. I will highlight applications concerning new drug modalities involving multi-specific small molecules and antibodies, and real-time binding measurements on living cancer cells.
Uli was trained in physics at TU Graz and completed his PhD scl in biophysics with Prof. Gerhard Abstreiter at TU Munich in 2005. He led a nanotechnology research group at the Walter Schottky Institute of TU Munich and was a junior fellow of the Institute of Advanced Study before founding Dynamic Biosensors GmbH in 2013, a company for research instruments, which enable the analysis of molecular interactions in drug discovery. Uli headed Dynamic Biosensors until it was acquired by Bruker in 2024.
Since 2024, he has been the director of the Kurt Schwabe Institute for Sensor Technologies, professor for Physical Chemistry at TU Dresden, and Chief Scientific Officer of Bruker Biosensors.
Uli’s research revolves around the analysis of molecular interactions, including methods to probe single cells and single molecules.
